AngioDynamics (ANGO) delivered a clean bottom-line beat in its fiscal first quarter, reporting an adjusted loss of $0.04 per share against a consensus estimate of -$0.10 and an Earnings Whisper number of -$0.06. That works out to a 33.3% surprise and 60.0% year-over-year earnings growth, as the adjusted loss narrowed from $0.10 a year ago. The top line told a different story. Revenue of $80.92 million rose 6.9% and landed essentially on the $80.94 million consensus. The beat was built almost entirely on margin, while full-year guidance was only reaffirmed. That is the central tension: profitability is improving faster than expected, but the growth engine is gradually losing speed.
The quality of the beat deserves scrutiny. GAAP gross margin jumped 410 basis points to 59.4%, driven by pricing, the mix shift toward Med Tech, and Costa Rica manufacturing savings. However, $1.2 million of tariff refunds flattered the result. Excluding them, gross margin would have been 57.8%. That is still a sharp improvement from 54.0% in the fourth quarter and 52.9% in the third, so the underlying trend is genuine. Adjusted EBITDA more than doubled to $5.0 million from $2.2 million, and the GAAP loss narrowed to $0.17 from $0.26. The problem is what comes next. The 54%-55% full-year gross margin guide sits well below the first quarter's level, and management again flagged a second-half step-down. The unchanged adjusted EPS range of -$0.29 to -$0.24 also implies meaningfully deeper losses over the remaining three quarters. One small wrinkle added confusion: the CFO cited a 55%-56% gross margin figure on the call, which conflicts with the formal 54%-55% guide.
Beneath the headline, revenue growth continues to decelerate. Total growth has slid from 8.8% and 8.9% in the second and third quarters of fiscal 2026 to 8.0% in the fourth quarter and 6.9% now. Med Tech, the strategic heart of the story, grew 13.2%, down from 19% in the third quarter and 16.7% in the fourth. Auryon extended its streak to 21 consecutive quarters of double-digit growth, but its 14.7% gain compares with roughly 18% in mid-fiscal 2026. Mechanical thrombectomy did return to growth at 6.7%, recovering from a 1.1% decline in the prior quarter. Within that business, AlphaVac surged 37.4%, while AngioVac remained down 5.9% year over year despite 9.1% sequential growth. NanoKnife was the standout, rising 29% to $8.3 million on record prostate procedures, with probe sales up 24.1% and capital sales up 53.5%. Med Device grew just 1.4%, consistent with the flat full-year expectation. Med Tech now accounts for 49% of revenue, up from 47%.
The call did preserve a credible longer-term growth narrative. Management received FDA IDE approval for the RELIEF feasibility study of NanoKnife in benign prostatic hyperplasia and attached a roughly $1.9 billion market estimate to the opportunity, after declining to size it last quarter. Several other initiatives are progressing:
- The company is working with additional Medicare contractors following the Palmetto coverage decision, with the goal of nationwide NanoKnife prostate coverage.
- The AlphaReturn IDE is enrolling strongly, with on-label status targeted early next calendar year.
- The AngioVac endocarditis study is also enrolling well.
- Additional tariff refunds are expected, although their timing is uncertain.
Naming Eric Honroth, formerly of Getinge, as CEO effective November 2 removes a leadership overhang that has lingered since the second quarter, though transition execution remains a risk. Bears have legitimate ammunition elsewhere as well. The guidance reaffirmation breaks a streak of raises through fiscal 2026. In addition, a seasonal $15.3 million operating cash burn cut cash to $34.0 million from $53.9 million, even though the balance sheet remains debt-free and management reaffirmed positive operating cash flow for the full year.
The market setup is more complicated than the surprise implies. Earnings Whispers investor sentiment remained positive but weakened, slipping from 0.24 to 0.14. Shares stand at $11.52, down 15.5% from the $13.64 open following the July report and 7.7% below the 200-day moving average of $12.48. The stock printed its inter-earnings high of $13.80 on report day, then fell to a quarterly low of $10.86 the following session, a sign that investors sold the reaffirmation rather than rewarded the beat. The supplied data also show a 52-week high of $16.29 on August 19 during the same period, which conflicts with the recorded quarterly high. Either way, the stock sits far below its recent peak. The trend readings lean negative, with AVWAP negative and price and momentum neutral.
The bottom line is that AngioDynamics proved it can expand margins and narrow losses faster than Wall Street expected. However, a tariff-aided gross margin, decelerating Med Tech growth, and an outlook that was held rather than raised leave the stock leaning on pipeline catalysts such as NanoKnife BPH and expanded prostate coverage to restore its growth premium.